UNIPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.45 TWD | +1.13% |
|
+3.07% | -9.12% |
| 04-24 | UniPharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | UniPharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 329.7 | 319.3 | 535.1 | 399.5 | 550.3 | 525.4 |
| Enterprise Value (EV) 1 | 113.8 | 141.2 | 363.8 | 231.1 | 391.5 | 351.5 |
| P/E ratio | -9.04 x | -12.8 x | -9.67 x | -5.37 x | -85.3 x | -24.3 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.04 x | 2.07 x | 3.86 x | 3.79 x | 4.3 x | 5.09 x |
| EV / Revenue | 0.7 x | 0.92 x | 2.62 x | 2.19 x | 3.06 x | 3.41 x |
| EV / EBITDA | -7.44 x | -6.38 x | -24 x | -6.6 x | -20.8 x | -16.2 x |
| EV / FCF | 3.01 x | -72.2 x | -28.6 x | -8.77 x | -25.4 x | 22.4 x |
| FCF Yield | 33.2% | -1.39% | -3.5% | -11.4% | -3.94% | 4.46% |
| Price to Book | 1 x | 0.8 x | 1.41 x | 1.34 x | 1.81 x | 1.7 x |
| Nbr of stocks (in thousands) | 26,787 | 35,201 | 35,201 | 35,201 | 35,501 | 35,501 |
| Reference price 2 | 12.31 | 9.070 | 15.20 | 11.35 | 15.50 | 14.80 |
| Announcement Date | 19-04-25 | 20-04-09 | 21-04-22 | 22-04-20 | 23-04-20 | 24-04-24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 161.7 | 154.3 | 138.6 | 105.4 | 128.1 | 103.2 |
| EBITDA 1 | -15.29 | -22.12 | -15.17 | -34.99 | -18.8 | -21.76 |
| EBIT 1 | -21.31 | -27.8 | -20.61 | -40.22 | -20.88 | -27.3 |
| Operating Margin | -13.17% | -18.02% | -14.87% | -38.17% | -16.3% | -26.45% |
| Earnings before Tax (EBT) 1 | -40.35 | -25.04 | -55.35 | -74.41 | -7.027 | -21.81 |
| Net income 1 | -40.35 | -25.04 | -55.35 | -74.41 | -6.446 | -21.81 |
| Net margin | -24.95% | -16.23% | -39.93% | -70.6% | -5.03% | -21.13% |
| EPS 2 | -1.361 | -0.7111 | -1.572 | -2.114 | -0.1817 | -0.6100 |
| Free Cash Flow 1 | 37.76 | -1.957 | -12.72 | -26.34 | -15.42 | 15.66 |
| FCF margin | 23.35% | -1.27% | -9.17% | -24.99% | -12.04% | 15.17% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 19-04-25 | 20-04-09 | 21-04-22 | 22-04-20 | 23-04-20 | 24-04-24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 216 | 178 | 171 | 168 | 159 | 174 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 37.8 | -1.96 | -12.7 | -26.3 | -15.4 | 15.7 |
| ROE (net income / shareholders' equity) | -10.3% | -5.98% | -14.2% | -22% | -2.34% | -7.08% |
| ROA (Net income/ Total Assets) | -3.17% | -3.75% | -2.96% | -6.58% | -3.83% | -5% |
| Assets 1 | 1,273 | 668 | 1,873 | 1,130 | 168.2 | 436.3 |
| Book Value Per Share 2 | 12.30 | 11.40 | 10.80 | 8.450 | 8.540 | 8.680 |
| Cash Flow per Share 2 | 6.100 | 5.700 | 5.340 | 2.160 | 1.800 | 1.910 |
| Capex 1 | 1.02 | 0.28 | 0.53 | 0.61 | 0.44 | 8.11 |
| Capex / Sales | 0.63% | 0.18% | 0.38% | 0.58% | 0.34% | 7.86% |
| Announcement Date | 19-04-25 | 20-04-09 | 21-04-22 | 22-04-20 | 23-04-20 | 24-04-24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -9.12% | 14.57M | |
| -15.55% | 270M | |
| +7.81% | 196M | |
| +26.13% | 77.74M | |
| +20.00% | 66.53M |
- Stock Market
- Equities
- 6621 Stock
- Financials UniPharma Co., Ltd.